Clinical trials of orphan medicines

The Lancet

Volumn 371, Issue 9629, 2008, Pages 2051-2055

  Buckley, Brendan M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANAGRELIDE; ARSENIC TRIOXIDE; BOSENTAN; CARGLUMIC ACID; CELECOXIB; CLOFARABINE; DASATINIB; DEFERASIROX; GALSULFASE; IBUPROFEN; ILOPROST; IMATINIB; LARONIDASE; MIGLUSTAT; MITOTANE; NITISINONE; OMEGA CONOTOXIN MVIIA; ORPHAN DRUG; OXYBATE SODIUM; PEGVISOMANT; PHOTOFRIN; RAZOXANE; SILDENAFIL; SITAXSENTAN; STIRIPENTOL; SUNITINIB; UNINDEXED DRUG; ZINC ACETATE;

ACROMEGALY; ADENOMATOUS POLYP; ADRENAL CORTEX CARCINOMA; BARRETT ESOPHAGUS; CATAPLEXY; CHRONIC MYELOID LEUKEMIA; CHRONIC PAIN; CLINICAL STUDY; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; DYSPLASIA; FABRY DISEASE; GASTROINTESTINAL STROMAL TUMOR; GAUCHER DISEASE; GLIOMA; GLYCOGEN STORAGE DISEASE TYPE 2; HOMOCYSTINURIA; HUMAN; HYPERAMMONEMIA; INCIDENCE; KIDNEY CARCINOMA; LENNOX GASTAUT SYNDROME; MAROTEAUX LAMY SYNDROME; MUCOPOLYSACCHARIDOSIS; NARCOLEPSY; PATENT DUCTUS ARTERIOSUS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PULMONARY HYPERTENSION; RARE DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SUPPORT GROUP; SURVIVAL RATE; SYSTEMIC SCLEROSIS; THROMBOCYTHEMIA; TREATMENT INDICATION; TYROSINEMIA; WILSON DISEASE;

EID: 44849084139     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60876-4     Document Type: Review

References (21)

1. Lilford R., Thornton J., and Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ 311 (1995) 1621-1625
2. European Union. Regulation (EC) No 141/2000 of the European Parliament and of the Council on Orphan Medicinal Products of 16 December 1999 and Commission Regulation (EC) No 847/2000 of 27 April 2000. Off J Euro Comm 43 (2000) L103/5-L103/8
3. Chiron C., Marchand M., Tran A., et al., for the STICLO study group. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet 356 (2000) 1638-1642
4. Anon. Note for guidance on statistical principles in clinical trials (1998), EMEA, London
5. Friedman L., Fuberg C., and DeMets D. Fundamentals of clinical trials. 3rd edn. (1998), ACCP, Kansas City
6. Committee for Medicinal Products for Human Use. Guideline on clinical trials in small populations (2006), EMEA, London
7. Berry D. A guide to drug discovery: Bayesian clinical trials. Nat Rev Drug Dis 5 (2006) 27-36
8. Freedman L., Spiegelhalter D., and Parmar M. The what, why and how of Bayesian clinical trials monitoring. Stat Med 13 (1994) 1371-1383
9. Sung L., and Feldman B. N-of-1 trials: innovative methods to evaluate complementary and alternative medicines in pediatric cancer. J Pediatr Hematol Oncol 28 (2006) 263-266
10. Jones B. Design and analysis of cross-over trials. 2nd edn. Monographs on statistics and applied probability (2003), CRC Press, London
11. Suri R., Metcalfe C., Wallis C., and Bush A. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol 37 (2004) 305-310
12. Backman C., and Harris S. Case studies, single-subject research, and N-of-1 randomized trials: comparisons and contrasts. Am J Phys Med Rehabil 78 (1999) 170-176
13. Cook D. Randomized trials in single subjects: the N of 1 study. Psychopharmacol Bull 32 (1996) 363-367
14. Bollert F., Paton J., Marshall T., Calvert J., Greening A., Innes J., and Scottish Cystic Fibrosis Group. Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Eur Respir J 13 (1999) 107-113
15. Lagakos S. Clinical trials and rare diseases. N Engl J Med 348 (2003) 2455-2456
16. Stallard N., and Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Stat Med 22 (2003) 689-703
17. Whitehead J. The design and analysis of sequential clinical trials. 2nd edn. (1997), Wiley, Chichester
18. Walshe J. The management of Wilson's disease with triethylene tetramine 2HC1 (Trien 2HC1). Prog Clin Biol Res 34 (1979) 271-280
19. Gunn T., Metrakos K., Riley P., Willis D., and Aranda J. Sequelae of caffeine treatment in preterm infants with apnea. J Pediatr 94 (1979) 106-109
20. Lubitz J., Freeman L., and Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223 (1973) 1109-1112
21. Schein P. Chemotherapeutic management of the hormone-secreting endocrine malignancies. Cancer 30 (1972) 1616-1626